iRhythm Technologies, Inc. (IRTC)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 265 | 323 | 411 | 493 | 592 | 747 | 825 | 887 |
| Operating profit | $m | -37 | -10 | ||||||
| Net profit | $m | -44 | -101 | -116 | -123 | -113 | -45 | -14 | -7 |
| EPS reported | $ | -1.39 | -0.43 | ||||||
| Operating cashflow per share | $ | 2.53 | 2.61 | ||||||
| Capex per share | $ | 1.45 | 1.43 | ||||||
| FCF per share | $ | 1.08 | 1.18 | ||||||
| Free cash flow | $m | 35 | 39 | ||||||
| Net debt | $m | 66 | 60 | ||||||
| Book value equity | $m | 153 | 186 | ||||||
| Book value per share | $ | 4.77 | 5.65 | ||||||
| Number of shares | m | 32 | 32.9 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 37.18 | 30.53 | ||||||
| P/S LTM | x | 7.60 | 6.88 | ||||||
| P/FCF LTM | x | 164.50 | 145.69 | ||||||
| EV/EBITDA LTM | x | -1,557.12 | 307.10 | ||||||
| EV/Sales LTM | x | 8.26 | 5.62 | ||||||
| Earnings Yield LTM | % | -0.78% | -0.34% | ||||||
| FCF Yield | % | +0.61% | +0.69% | ||||||
| Quality | |||||||||
| ROE | % | -29.17% | -8.97% | ||||||
| ROIC | % | -4.16% | -1.05% | ||||||
| Operating margin | % | -4.93% | -1.17% | ||||||
| Gross margin | % | +70.57% | +71.45% | ||||||
| FCF/Sales | % | +4.62% | +4.72% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +26.24% | +39.45% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.05 | 0.05 | ||||||
| Net Debt/EBITDA | x | -124.89 | 23.91 | ||||||
| EBIT/Net interest | x | -2.80 | -0.73 | ||||||
| Net debt/market cap | % | +11.44% | +15.71% | ||||||
| Net debt/Equity | x | 0.43 | 0.32 | ||||||
| Gross debt/equity | x | 4.79 | 3.91 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
iRhythm Technologies, Inc. (IRTC)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free